

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 42245

Title: Immune checkpoint inhibitor-induced colitis: A comprehensive review

Reviewer's code: 00225291

Reviewer's country: Spain

Science editor: Fang-Fang Ji

Date sent for review: 2018-09-21

Date reviewed: 2018-10-01

Review time: 3 Hours, 10 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Some minor corrections are suggested. I attach a revised version of the manuscript, showing some of them. In addition, I encourage authors to: 1.- Provide accurate reference for figure 2 2.- Provide accurate reference for table 2 3.- Comment on the assertion, when discussing Mechanism of irAEs that: "Consequently, it has been



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

hypothesized that antibody to CTLA4 might diminish Treg cells and accordingly induce autoimmunity [27]" Is this so now? Reference 27 dates back to 2005. Could authors update this point?

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 42245

Title: Immune checkpoint inhibitor-induced colitis: A comprehensive review

Reviewer's code: 01589311

Reviewer's country: Brazil

Science editor: Fang-Fang Ji

Date sent for review: 2018-10-11

Date reviewed: 2018-10-13

Review time: 14 Hours, 2 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Comments to the Author This is an interesting review study by Som and colleagues, examining the widespread and successful use of immune checkpoint inhibitors (ICI) immunotherapies, however, calling the attention for common immune-related adverse events (irAEs). In particular, the authors focus on the ubiquitous development of colitis



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

secondary to the use of ICI for cancer treatment, including pathogenic and clinical aspects, in addition to medical management. Specific comments to Authors: In terms of contents, the approach is interesting and well structured. However, it would be interesting to further discuss differential diagnosis, especially regarding IBD. Which parameters should be used to establish differential diagnosis and to rule out IBD, for example? Another important point emerges from the fact that some patients with irAEs are treated with anti-TNF-alpha agents. Considering that anti-TNF have some relative and absolute contraindications, including some types of cancers, authors should be more specific on that issue.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 42245

Title: Immune checkpoint inhibitor-induced colitis: A comprehensive review

Reviewer's code: 02861616

Reviewer's country: Australia

Science editor: Fang-Fang Ji

Date sent for review: 2018-10-11

Date reviewed: 2018-10-14

Review time: 13 Hours, 3 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input checked="" type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The manuscript is a review of immune checkpoint induced colitis, and includes a mechanistic overview followed by diagnosis, management and the potential for prevention. The topic is novel, under-explored and, as the authors suggest, has the potential to increase in prevalence given the relatively recent use of these drugs and



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

their potential for expansion into widespread use for cancer treatment. The quality is high and there are only minor comments: 1: Mechanism of action section, sentence starting "CTLA-4 is a negative regulator of T-cell-mediated....." There is a grammatical error between 'responses cell' in this sentence. 2: Mechanism of irAEs section, sentence starting 'Consequently, it has been hypothesised that antibody to'. There is a grammatical error also here. 3: Epidemiology section. 2nd paragraph 'Beck et. al.'. The type of cancer(s) treated in the Beck reference should be included.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No